Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
Year: 2018
Type: article
Abstract: Background: N+I demonstrated superior objective response rate (ORR) and overall survival (OS) vs sunitinib in pts with IMDC intermediate/poor (int/poor)-risk aRCC in the phase 3 CheckMate 214 trial. Further characterization of response may inform clinical practice.
Source: Annals of Oncology
Institutions: Cleveland Clinic, The University of Texas MD Anderson Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, Beth Israel Deaconess Medical Center, Jena University Hospital, Policlinico San Matteo Fondazione, Barts Cancer Institute, BC Cancer Agency, Westmead Hospital, Macquarie University, Fred Hutch Cancer Center, Duke Medical Center, Medizinische Hochschule Hannover, Dana-Farber Cancer Institute, Bristol-Myers Squibb (United States), The University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2897960737